About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Splenomegaly in Polycythemia Vera: Clinical Significance and Relation to Myelofibrosis and Survival
By
Richard T. Silver
2 Videos
321 views
December 16, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
22:37
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Acute Leukemia and MDS - Highlig…
Feat.
T. Badar
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
08:18
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Strategies for Hematocrit Control…
Feat.
A. Zhou
16:55
Moffitt Cancer Center
Making Sense of the New Classification Systems for MDS in 2024
Feat.
R. Komrokji
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
12:36
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Myeloid for Measure - New Therapeutics in…
Feat.
A. Patel
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
44:26
University of Colorado Division of Hematology
Novel Therapies in AML and MDS
Feat.
D. Pollyea
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
13:07
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax With Azacitidine for Pts With Tr…
Feat.
J. Garcia
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
31:53
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
Feat.
R. Childs
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
09:27
ASH 2022 Conference Coverage
MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…
Feat.
M. McMullin
32:04
Moffitt Cancer Center
Experts Discuss the Latest Data in Myeloid Diseases
Feat.
A. Kuykendall,
R. Komrokji,
O. Chan,
D. Sallman
